Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS

Next Previous
X
Search
Trial Profile

A PHASE 4, MULTICENTER, OPEN-LABEL SAFETY STUDY OF CRISABOROLE OINTMENT 2% IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Acronyms CARE1; CrisADe CARE 1
  • Sponsors Pfizer

    • Most Recent Events

    • 22 Feb 2023 Results of an analysis impact of crisaborole on sleep outcomes in pediatric patients atopic dermatitis from three clinical studies: CORE-1, CORE-2 and CrisADe CARE 1 study published in the Dermatology and Therapy
    • 25 Apr 2021 Results of post-hoc analysis assessing the efficacy and safety of crisaborole by body region in infants presented at the American Academy of Dermatology Virtual Meeting Experience 2021
    • 24 Mar 2020 Results published in the American Journal of Clinical Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top